home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

BeiGene, Ltd. - American Depositary Shares (NQ:BGNE)

184.71 UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 31, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BeiGene, Ltd. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Bragar Eagel & Squire, P.C. Is Investigating EPAM, Castle, BeiGene and Fox and Encourages Investors to Contact the Firm

June 30, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2023 ↗

June 30, 2023

Via Benzinga

What's Happening With Beigene Shares During Wednesday's Session ↗

June 21, 2023

Beigene Ltd (NASDAQ: BGNE) shares are trading lower by 3.41% to $185.03 Wednesday morning on downward momentum following Tuesday weakness.

Via Benzinga

Recap: BeiGene Q1 Earnings ↗

May 04, 2023

Via Benzinga

Why This BeiGene Analyst Slashes Forecast By Almost 42% ↗

June 30, 2023

BeiGene Ltd (NASDAQ: BGNE) declined in early trading on Friday, maintaining its downward trajectory through the week amid weakness in Chinese stocks.

Via Benzinga

NVIDIA To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Friday ↗

June 30, 2023

Truist Securities boosted the price target for BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from $125 to $140. Truist Securities analyst Robyn Karnauskas maintained a Buy rating. BioMarin Pharmaceutical...

Via Benzinga

BEIGENE ALERT: Bragar Eagel & Squire, P.C. is Investigating BeiGene, Ltd. on Behalf of BeiGene Stockholders and Encourages Investors to Contact the Firm

June 26, 2023

From Bragar Eagel & Squire, P.C.

Via Business Wire

BGNE INVESTOR NEWS: ROSEN, A LEADING LAW FIRM, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation – BGNE

June 17, 2023

From The Rosen Law Firm PA

Via GlobeNewswire

Kirby McInerney LLP Continues Investigation of Shareholder Claims Against BeiGene, Ltd. (BGNE)

June 16, 2023

From Kirby McInerney LLP

Via Business Wire

BGNE LOSS ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation - BGNE

June 16, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Intellectual Property Lawsuit

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm

June 16, 2023

From The Schall Law Firm

Via Business Wire

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm

June 15, 2023

From The Schall Law Firm

Via Business Wire

BGNE INVESTOR NEWS: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation – BGNE

June 15, 2023

From The Rosen Law Firm, P.A.

Via Business Wire

AbbVie Says BeiGene's Flagship Blood Cancer Drug Infringes Imbruvica Patent ↗

June 15, 2023

BeiGene Ltd (NASDAQ: BGNE) says it is aware that Pharmacyclics LLC has filed a complaint alleging that BeiGene's blood cancer therapy Brukinsa (zanubrutinib) infringes a Pharmacyclics

Via Benzinga

BeiGene to Vigorously Defend Patent Infringement Allegations by Pharmacyclics

June 15, 2023

From BeiGene

Via Business Wire

Why MicroVision Shares Are Trading Higher By 28%; Here Are 20 Stocks Moving Premarket ↗

June 15, 2023

Gainers EdtechX Holdings Acquisition Corp. II (NASDAQ: EDTX) shares gained 139.8% to $26.54 in pre-market trading.

Via Benzinga

Gambling.com, Editas Medicine And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

June 15, 2023

U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress

June 09, 2023

From BeiGene

Via Business Wire

BRUKINSA® Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia

May 30, 2023

From BeiGene, Ltd.

Via Business Wire

BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio

May 25, 2023

From BeiGene

Via Business Wire

Mirati's Sitravatinib Flunks Phase 3 Combo Therapy Study In Type Of Lung Cancer Setting ↗

May 25, 2023

Via Benzinga

BeiGene to Present at Upcoming Investor Conferences

May 24, 2023

From BeiGene

Via Business Wire

Immix Biopharma's Subsidiary Says Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis ↗

May 22, 2023

Immix Biopharma Inc's (NASDAQ: IMMX) subsidiary Nexcella Inc announced updated AL Amyloidosis clinical data from its ongoing Phase 1b/2a NEXICART-1 study of its BCMA-targeted chimeric antigen receptor...

Via Benzinga

The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries

May 17, 2023

From BeiGene

Via Business Wire

BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China

May 06, 2023

From BeiGene

Via Business Wire

BeiGene Reports First Quarter 2023 Financial Results and Corporate Developments

May 04, 2023

From BeiGene, Ltd.

Via Business Wire

What's Going On With Immix Biopharma Stock Today ↗

May 03, 2023

Immix Biopharma Inc (NASDAQ: IMMX) announced early interim data from IMMINENT-01 Phase 1b/2a trial combining tissue-specific therapeutic IMX-110 with BeiGene Ltd (NYSE: BGNE) / Novartis AG'

Via Benzinga

BeiGene to Highlight Broad Oncology Portfolio at the 2023 ASCO Annual Meeting

April 26, 2023

From BeiGene

Via Business Wire

3 Top Biotech Stocks Defying the Bear Market ↗

April 25, 2023

All three companies have therapies with strong sales potential.

Via The Motley Fool

BeiGene Announces Goals Focused on Sustainable Growth and Workforce Diversity in New ESG Report

April 25, 2023

From BeiGene

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com